MIRA Pharmaceuticals, Inc. Interest Income (Expense), Net
MIRA Pharmaceuticals, Inc. (MIRA) reported Interest Income (Expense), Net of $35.13 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2026-08-12
- MIRA Pharmaceuticals, Inc. interest income (expense), net for the quarter ending 2026-06-30 was $35.13K, a 307.40% increase year-over-year.
- MIRA Pharmaceuticals, Inc. interest income (expense), net for the quarter ending 2026-03-31 was $44.91K, a 109.65% increase year-over-year.
- MIRA Pharmaceuticals, Inc. interest income (expense), net for the quarter ending 2025-12-31 was $53.17K, a 39.54% increase year-over-year.
- MIRA Pharmaceuticals, Inc. interest income (expense), net for the quarter ending 2025-09-30 was $15.70K, a 58.42% decline year-over-year.
- MIRA Pharmaceuticals, Inc. interest income (expense), net for fiscal 2025 was $98.91K, a 40.30% decline from fiscal 2024.
- MIRA Pharmaceuticals, Inc. interest income (expense), net for fiscal 2024 was $165.67K.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 6 month as first filed | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $35.13K 10-Q · filed 2026-08-12 | $80.04K 10-Q · filed 2026-08-12 | $133.21K derived: sum of 3 quarters · filed 2026-08-12 | $148.91K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $44.91K 10-Q · filed 2026-05-14 | $98.08K derived: sum of 2 quarters · filed 2026-05-14 | $113.78K derived: sum of 3 quarters · filed 2026-05-14 | $122.40K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $53.17K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $68.87K derived: sum of 2 quarters · filed 2026-03-31 | $77.49K derived: sum of 3 quarters · filed 2026-08-12 | $98.91K 10-K · filed 2026-03-31 | |
| 2025-09-30 | $15.70K 10-Q · filed 2025-11-13 | $24.32K derived: sum of 2 quarters · filed 2026-08-12 | $45.74K 10-Q · filed 2025-11-13 | $83.85K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $8.62K 10-Q · filed 2026-08-12 | $30.04K 10-Q · filed 2026-08-12 | $29.81K 10-Q · filed 2025-08-14 | $68.15K derived: sum of 3 quarters · filed 2026-08-12 | $105.90K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $21.42K 10-Q · filed 2026-05-14 | $59.53K derived: sum of 2 quarters · filed 2026-05-14 | $97.28K derived: sum of 3 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $38.10K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $75.86K derived: sum of 2 quarters · filed 2026-03-31 | $165.67K 10-K · filed 2026-03-31 | ||
| 2024-09-30 | $37.75K 10-Q · filed 2025-11-13 | $127.56K 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $89.81K 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |